CR9266A - Agonistas del peptido 1 similar al glucagon, composiciones, metodos y usos - Google Patents

Agonistas del peptido 1 similar al glucagon, composiciones, metodos y usos

Info

Publication number: CR9266A
Authority: CR; Costa Rica
Prior art keywords: glucagon; compositions; methods; similar; peptide agonists
Prior art date: 2004-12-22

Application number

CR9266A

Other languages

English (en)

Inventor

T O'neil Karyn

O'neil John

Picha Kristen

Xu Gang

Lark Michael

Original Assignee

Centocor Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-12-22

Filing date

2007-07-20

Publication date

2008-09-09

2007-07-20 Application filed by Centocor Inc filed Critical Centocor Inc

2008-09-09 Publication of CR9266A publication Critical patent/CR9266A/es

Links

102000051325 Glucagon Human genes 0.000 title 1
108060003199 Glucagon Proteins 0.000 title 1
239000000556 agonist Substances 0.000 title 1
MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 title 1
229960004666 glucagon Drugs 0.000 title 1
239000000203 mixture Substances 0.000 title 1
108090000765 processed proteins & peptides Proteins 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/575—Hormones
- G01N2333/605—Glucagons
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
- G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Immunology (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Endocrinology (AREA)
Animal Behavior & Ethology (AREA)
Molecular Biology (AREA)
Public Health (AREA)
Gastroenterology & Hepatology (AREA)
Hematology (AREA)
Biochemistry (AREA)
Diabetes (AREA)
Biomedical Technology (AREA)
Urology & Nephrology (AREA)
Zoology (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Toxicology (AREA)
Physics & Mathematics (AREA)
Pathology (AREA)
Genetics & Genomics (AREA)
Biotechnology (AREA)
Cell Biology (AREA)
Microbiology (AREA)
Biophysics (AREA)
Food Science & Technology (AREA)
General Physics & Mathematics (AREA)
Analytical Chemistry (AREA)
Emergency Medicine (AREA)
Obesity (AREA)

CR9266A 2004-12-22 2007-07-20 Agonistas del peptido 1 similar al glucagon, composiciones, metodos y usos CR9266A (es)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US63831304P	2004-12-22	2004-12-22

Publications (1)

Publication Number	Publication Date
CR9266A true CR9266A (es)	2008-09-09

Family

ID=37962937

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CR9266A CR9266A (es)	2004-12-22	2007-07-20	Agonistas del peptido 1 similar al glucagon, composiciones, metodos y usos

Country Status (17)

Country	Link
US (1)	US20070128193A1 (es)
EP (1)	EP1843788A4 (es)
JP (1)	JP2008525477A (es)
KR (1)	KR20070090036A (es)
CN (1)	CN101415439A (es)
AU (1)	AU2005337493A1 (es)
BR (1)	BRPI0519241A2 (es)
CA (1)	CA2592065A1 (es)
CR (1)	CR9266A (es)
EA (1)	EA200701362A1 (es)
IL (1)	IL183940A0 (es)
MX (1)	MX2007007602A (es)
NI (1)	NI200700158A (es)
NO (1)	NO20073814L (es)
SG (1)	SG158158A1 (es)
WO (1)	WO2007046834A2 (es)
ZA (1)	ZA200706030B (es)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US9006175B2 (en)	1999-06-29	2015-04-14	Mannkind Corporation	Potentiation of glucose elimination
WO2003080149A2 (en)	2002-03-20	2003-10-02	Mannkind Corporation	Inhalation apparatus
ATE486064T1 (de)	2004-08-20	2010-11-15	Mannkind Corp	Katalyse der diketopiperazinsynthese
HUE025151T2 (en)	2004-08-23	2016-01-28	Mannkind Corp	Diceto-piperazine salts for drug delivery
EP1874339A1 (en) *	2005-04-21	2008-01-09	Gastrotech Pharma A/S	Pharmaceutical preparations of a glp-1 molecule and an anti-emetic drug
KR101486397B1 (ko)	2005-09-14	2015-01-28	맨카인드 코포레이션	활성제에 대한 결정질 미립자 표면의 친화력의 증가를 기반으로 하는 약물 제제화의 방법
WO2007081654A2 (en) *	2005-12-28	2007-07-19	Zoltan Laboratories Llc	Compositions and methods to enhance viability and function of islet cells
KR20080096809A (ko)	2006-02-22	2008-11-03	맨카인드 코포레이션	디케토피페라진 및 활성제를 포함하는 마이크로입자의 약학특성의 개선 방법
TW200843794A (en)	2006-12-21	2008-11-16	Centocor Inc	Use of long-acting GLP-1 receptor agonists to improve insulin sensitivity and lipid profiles
WO2008092209A1 (en) *	2007-02-01	2008-08-07	Arana Therapeutics Limited	Protein construct with improved properties
US8485180B2 (en)	2008-06-13	2013-07-16	Mannkind Corporation	Dry powder drug delivery system
ES2929343T3 (es)	2008-06-13	2022-11-28	Mannkind Corp	Inhalador de polvo seco accionado por aspiración para la administración de fármacos
MX2010014240A (es)	2008-06-20	2011-03-25	Mankind Corp	Un metodo y aparato interactivo para perfilar en tiempo real esfuerzos de inhalacion.
TWI494123B (zh)	2008-08-11	2015-08-01	Mannkind Corp	超快起作用胰島素之用途
US20110020392A1 (en) *	2008-10-14	2011-01-27	Salubrious Pharmaceutical, Llc	Process for treatment of rheumatoid arthritis, tremors/parkinson's disease, multiple sclerosis and non-viral based cancers
EP3228320B1 (de)	2008-10-17	2019-12-18	Sanofi-Aventis Deutschland GmbH	Kombination von einem insulin und einem glp-1-agonisten
PL2373681T3 (pl)	2008-12-10	2017-07-31	Glaxosmithkline Llc	Kompozycje farmaceutyczne albiglutydu
US8314106B2 (en)	2008-12-29	2012-11-20	Mannkind Corporation	Substituted diketopiperazine analogs for use as drug delivery agents
WO2010105094A1 (en)	2009-03-11	2010-09-16	Mannkind Corporation	Apparatus, system and method for measuring resistance of an inhaler
MY157166A (en)	2009-06-12	2016-05-13	Mankind Corp	Diketopiperazine microparticles with defined specific surface areas
EP3202394A1 (de)	2009-07-06	2017-08-09	Sanofi-Aventis Deutschland GmbH	Wässrige insulinzubereitungen enthaltend methionin
WO2011056889A1 (en)	2009-11-03	2011-05-12	Mannkind Corporation	An apparatus and method for simulating inhalation efforts
PT2554183T (pt)	2009-11-13	2018-07-09	Sanofi Aventis Deutschland	Composição farmacêutica que compreende um agonista de glp-1, uma insulina e metionina
PE20121316A1 (es)	2009-11-13	2012-10-05	Sanofi Aventis Deutschland	Composicion farmaceutica que comprende un agonista de glp-1 y metionina
WO2011140176A1 (en)	2010-05-04	2011-11-10	Glaxosmithkline Llc	Methods for treating or preventing cardiovascular disorders and providing cardiovascular protection
EP2569000B1 (en)	2010-05-13	2017-09-27	Indiana University Research and Technology Corporation	Glucagon superfamily peptides exhibiting nuclear hormone receptor activity
AU2011202239C1 (en)	2010-05-19	2017-03-16	Sanofi	Long-acting formulations of insulins
BR112012033060A2 (pt)	2010-06-21	2018-02-27	Mannkind Corp	métodos de sistema de liberação de fármaco em pó seco
EP2588126A4 (en)	2010-06-24	2015-07-08	Univ Indiana Res & Tech Corp	AMID-BASED GLUCAGON SUPERFAMILY PEPTIDE PRODRUGS
US20140148384A1 (en)	2010-08-30	2014-05-29	Sanofi-Aventis Deutschland Gmbh	Use of ave0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2
US20140045754A1 (en) *	2011-01-19	2014-02-13	Joern Drustrup	Glp-1 compositions
AU2012236150B2 (en)	2011-04-01	2016-03-31	Mannkind Corporation	Blister package for pharmaceutical cartridges
US9821032B2 (en)	2011-05-13	2017-11-21	Sanofi-Aventis Deutschland Gmbh	Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
WO2012174472A1 (en)	2011-06-17	2012-12-20	Mannkind Corporation	High capacity diketopiperazine microparticles
US9950038B2 (en) *	2011-08-05	2018-04-24	The Trustees Of The Universiy Of Pennsylvania	Methods and compositions for inhibiting delayed graft function
CN108079281A (zh)	2011-08-29	2018-05-29	赛诺菲-安万特德国有限公司	用于2型糖尿病患者中的血糖控制的药物组合
TWI559929B (en)	2011-09-01	2016-12-01	Sanofi Aventis Deutschland	Pharmaceutical composition for use in the treatment of a neurodegenerative disease
BR112014009686A2 (pt)	2011-10-24	2018-08-07	Mannkind Corp	composição analgésica inalável, pó seco e método para tratar dor
CA2847246A1 (en)	2011-11-17	2013-05-23	Indiana University Research And Technology Corporation	Glucagon superfamily peptides exhibiting glucocorticoid receptor activity
CA2864655A1 (en) *	2012-03-01	2013-09-06	Yeda Research And Development Co. Ltd.	Hsp60 derived peptides and peptide analogs for suppression and treatment of non-autoimmune diabetes
AU2013289957B2 (en)	2012-07-12	2017-02-23	Mannkind Corporation	Dry powder drug delivery systems and methods
WO2014066856A1 (en)	2012-10-26	2014-05-01	Mannkind Corporation	Inhalable influenza vaccine compositions and methods
KR102246914B1 (ko)	2013-03-15	2021-04-30	맨카인드 코포레이션	미세결정성 디케토피페라진 조성물 및 방법
DK2983697T3 (en)	2013-04-03	2019-02-25	Sanofi Sa	TREATMENT OF DIABETES MELLITUS WITH LONG-EFFECTIVE FORMULATIONS OF INSULIN
CN114848614A (zh)	2013-07-18	2022-08-05	曼金德公司	热稳定性干粉药物组合物和方法
EP3030294B1 (en)	2013-08-05	2020-10-07	MannKind Corporation	Insufflation apparatus
US10307464B2 (en)	2014-03-28	2019-06-04	Mannkind Corporation	Use of ultrarapid acting insulin
US10561806B2 (en)	2014-10-02	2020-02-18	Mannkind Corporation	Mouthpiece cover for an inhaler
TWI758239B (zh)	2014-12-12	2022-03-21	德商賽諾菲阿凡提斯德意志有限公司	甘精胰島素/利司那肽固定比率配製劑
TWI748945B (zh)	2015-03-13	2021-12-11	德商賽諾菲阿凡提斯德意志有限公司	第２型糖尿病病患治療
TW201705975A (zh)	2015-03-18	2017-02-16	賽諾菲阿凡提斯德意志有限公司	第２型糖尿病病患之治療
EP3289074B1 (en) *	2015-04-28	2023-10-04	Université de Strasbourg	Clinical gene signature-based human cell culture model and uses thereof
CN105504026B (zh) *	2015-12-24	2018-12-07	广东医科大学	一种pac1-r和glp-1r的双向激动剂ot23及应用
CN107474136B (zh) *	2016-06-08	2023-03-07	上海交通大学医学院	增强激动型抗体活性的抗体重链恒定区序列
TWI829687B (zh)	2018-05-07	2024-01-21	丹麥商諾佛儂迪克股份有限公司	包含glp-1促效劑與n-(8-(2-羥基苯甲醯基)胺基)辛酸之鹽的固體組成物
CA3181300A1 (en)	2020-06-03	2021-12-09	Christoffer CLEMMENSEN	Glp1r agonist nmdar antagonist conjugates

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5614492A (en) *	1986-05-05	1997-03-25	The General Hospital Corporation	Insulinotropic hormone GLP-1 (7-36) and uses thereof
UA93662C2 (uk) *	2000-12-07	2011-03-10	Эли Лилли Энд Компани	Гетерологічний пептидильований глюкагон-подібний білок та його застосування для виготовлення лікарського засобу для лікування пацієнтів, що страждають на ожиріння або інсулінонезалежний цукровий діабет
US20020187926A1 (en) *	2001-03-07	2002-12-12	Knudsen Liselotte Bjerre	Combined use of derivatives of GLP-1 analogs and PPAR ligands
WO2004002424A2 (en) *	2002-06-28	2004-01-08	Centocor, Inc.	Mammalian epo mimetic ch1 deleted mimetibodies, compositions, methods and uses
KR20070004078A (ko) *	2004-03-31	2007-01-05	센토코 인코포레이티드	인간 ｇｌｐ-1 모방체, 조성물, 방법 및 용도

2005
- 2005-12-22 CA CA002592065A patent/CA2592065A1/en not_active Abandoned
- 2005-12-22 AU AU2005337493A patent/AU2005337493A1/en not_active Abandoned
- 2005-12-22 WO PCT/US2005/046602 patent/WO2007046834A2/en not_active Ceased
- 2005-12-22 KR KR1020077016979A patent/KR20070090036A/ko not_active Withdrawn
- 2005-12-22 MX MX2007007602A patent/MX2007007602A/es not_active Application Discontinuation
- 2005-12-22 EP EP05858658A patent/EP1843788A4/en not_active Withdrawn
- 2005-12-22 CN CNA2005800484969A patent/CN101415439A/zh active Pending
- 2005-12-22 BR BRPI0519241-2A patent/BRPI0519241A2/pt not_active Application Discontinuation
- 2005-12-22 US US11/315,728 patent/US20070128193A1/en not_active Abandoned
- 2005-12-22 EA EA200701362A patent/EA200701362A1/ru unknown
- 2005-12-22 JP JP2007548473A patent/JP2008525477A/ja active Pending
- 2005-12-22 SG SG200908512-7A patent/SG158158A1/en unknown
2007
- 2007-06-14 IL IL183940A patent/IL183940A0/en unknown
- 2007-06-19 NI NI200700158A patent/NI200700158A/es unknown
- 2007-07-20 CR CR9266A patent/CR9266A/es not_active Application Discontinuation
- 2007-07-20 ZA ZA200706030A patent/ZA200706030B/xx unknown
- 2007-07-20 NO NO20073814A patent/NO20073814L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
WO2007046834A2 (en)	2007-04-26
EP1843788A2 (en)	2007-10-17
NI200700158A (es)	2008-05-13
MX2007007602A (es)	2007-12-07
US20070128193A1 (en)	2007-06-07
IL183940A0 (en)	2007-10-31
ZA200706030B (en)	2009-12-30
NO20073814L (no)	2007-09-14
EA200701362A1 (ru)	2008-08-29
CA2592065A1 (en)	2007-04-26
BRPI0519241A2 (pt)	2009-01-06
CN101415439A (zh)	2009-04-22
AU2005337493A1 (en)	2007-04-26
JP2008525477A (ja)	2008-07-17
EP1843788A4 (en)	2009-11-18
WO2007046834A3 (en)	2009-06-18
SG158158A1 (en)	2010-01-29
KR20070090036A (ko)	2007-09-04

Legal Events

Date	Code	Title	Description
2012-09-20	FA	Abandonment or withdrawal (granting procedure)

Publication	Publication Date	Title
CR9266A (es)	2008-09-09	Agonistas del peptido 1 similar al glucagon, composiciones, metodos y usos
CR8706A (es)	2009-01-16	Mimeticuerpos de peptido-1 similar a glucagon de humano, composiciones, metodos, usos
CR10619A (es)	2009-06-04	Mimeticuerpos de peptido-1 similar a glucagon de humano, composiciones, metodos y usos
FR2900573B1 (fr)	2014-05-16	Nouvelles compositions cosmetiques renfermant au moins un peptide contenant au moins un cycle aromatique bloque
CR8642A (es)	2008-11-28	Compuestos, composiciones farmaceuticas y metodos para su uso en el tratameinto de desordenes metabolicos
PT1971366E (pt)	2014-11-06	Anticorpos humanos anti-il-23, composições, métodos e usos
BRPI0618904A2 (pt)	2016-09-13	composto, composição farmacêutica, e, uso do composto
TWI347313B (en)	2011-08-21	Novel substituted phenoxyacetic acids,pharmaceutical composition comprising them,and use thereof
FR2885904B1 (fr)	2007-07-06	Nouveaux derives du fluorene, compositions les contenant et utilisation
DK1827412T3 (da)	2014-02-10	Sammensætninger til anvendelse i kirurgi
DK2158281T3 (da)	2013-10-14	Farvepigmenteret laksammensætning med høj dækkeevne, forøget ridsefasthed, og let-at-rengøre egenskaber
ATE417648T1 (de)	2009-01-15	Stifte zusammensetzungen
DE602005012006D1 (de)	2009-02-12	Haarkosmetische Zusammensetzung
DE602005021571D1 (de)	2010-07-15	Haarkosmetische Zusammensetzung
DE602004024220D1 (de)	2009-12-31	Pharmazeutische modafinil-zusammensetzungen mit modifizierter freisetzung
EP1683510A4 (en)	2010-02-17	COSMETIC COMPOSITION
DE602004019101D1 (de)	2009-03-05	Stift zusammensetzungen
ITRM20060367A1 (it)	2008-01-14	Muteine del hngf usi terapeutici e composizioni farmaceutiche
DK1812120T3 (da)	2015-07-27	Hudbeskyttende, alkalinitetskontrollerende præparat og anvendelsen deraf
DK1784174T3 (da)	2012-12-10	Famaceutisk sammensætning omfattende gabapentin
IL186307A0 (en)	2008-01-20	Human glp-1 mimetibodies, compositions, methods and uses
FR2863874B1 (fr)	2006-03-17	Composition demaquillante
CL2004000184A1 (es)	2005-04-22	Forma polimorfa cristalina del monohidrato de 4-ciclopentilresorcinol, composicion farmaceutica y su uso para reducir la pigmentacion.
FR2879924B1 (fr)	2007-06-15	Composition cosmetique amincissante
FR2862871B1 (fr)	2008-05-30	Composition cosmetique anti-pollution